Spectrum Pharmaceuticals, Inc.

• In February 2010, Topotarget outlicensed North American and Indian rights on belinostat to Spectrum Pharmaceuticals
• Under the terms of the agreement, Spectrum Pharmaceuticals made an upfront payment of USD 30 million and took over 100% funding of the PTCL BELIEF trial
• In September 2011, Spectrum Pharmaceuticals completed recruitment i.e. Last Patient First Visit of the PTCL BELIEF trial and is targeting submission of an NDA on belinostat for the orphan drug indication PTCL in end 2012
• Resources for co-development in additional indications will have cost sharing, with Spectrum Pharmaceuticals contributing 70% and Topotarget contributing 30%
• Further indications such as cancer of unknown primary (CUP), ovarian cancer, and non-small cell lung cancer (NSCLC) are being considered
• Topotarget is eligible to receive milestone payments upon successful achievement of certain development and commercial milestones of up to USD 320 million as well as double-digit royalties on sales in addition to the upfront payment
• The first expected milestone will be upon acceptance to file by the FDA, which can happen approximately 60 days after the submission of the NDA to the FDA

For more information on Spectrum Pharmaceuticals, please visit www.sppirx.com